Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

June 2, 2022

Study Completion Date

June 2, 2022

Conditions
Gastric and Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

AMG 910

IV Infusion

Trial Locations (20)

5020

Landeskrankenhaus Salzburg, Salzburg

10002

National Taiwan University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

20246

Universitaetsklinikum Hamburg Eppendorf Onkologisches Zentrum, Hamburg

27157

Wake Forest Baptist Health, Winston-Salem

81377

Klinikum der Universität München Campus Grosshadern, München

81675

Klinikum rechts der Isar, München

91010

City of Hope National Medical Center, Duarte

92868

University of California at Irvine Medical Center, Orange

94805

Institut Gustave Roussy, Villejuif

04103

Universitätsklinikum Leipzig, Leipzig

464-8681

Aichi Cancer Center, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa-shi

104-0045

National Cancer Center Hospital, Chuo-ku

1081HV

Amsterdam UMC - location VUmc, Amsterdam

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08035

Hospital Universitari Vall d Hebron, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY